candesartan has been researched along with Hyperkalemia in 7 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Hyperkalemia: Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether the angiotensin-receptor blocker candesartan compared with placebo affects microalbuminuria incidence or rate of change in albuminuria in type 1 and type 2 diabetes." | 9.14 | Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. ( Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2009) |
| "We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function." | 7.73 | Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. ( Fujii, H; Inenaga, T; Kawano, Y; Nakahama, H; Nakamura, S; Yoshihara, F, 2005) |
| "Candesartan cilexetil is a nonpeptide selective blocker of the angiotensin II receptor sub-type 1." | 6.43 | Candesartan in heart failure. ( Chonlahan, JS; Germany, RE; Ripley, TL, 2006) |
| "To determine whether the angiotensin-receptor blocker candesartan compared with placebo affects microalbuminuria incidence or rate of change in albuminuria in type 1 and type 2 diabetes." | 5.14 | Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. ( Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2009) |
| "The addition of the angiotensin II type 1 receptor blocker (ARB) candesartan to a angiotensin-converting enzyme inhibitor (ACEI) has been associated with improved clinical outcomes in patients with heart failure." | 5.14 | Angiotensin receptor blocker therapy for heart failure patients: is combination treatment a feasible prospect? ( Dubrey, SW; Grocott-Mason, R; McDonagh, S; Mehta, PA; Phillips, J, 2009) |
| "Participants in the CHARM (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity) (n = 7,599) Program were randomized to standard heart failure therapy plus candesartan or placebo, titrated as tolerated to a target of 32 mg once daily with recommended monitoring of serum potassium and creatinine." | 3.74 | Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. ( Desai, AS; Dunlap, ME; Granger, CB; Hainer, JW; McMurray, JJ; Michelson, EL; Olofsson, B; Pfeffer, MA; Solomon, SD; Swedberg, K; Young, JB; Yusuf, S, 2007) |
| "We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function." | 3.73 | Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. ( Fujii, H; Inenaga, T; Kawano, Y; Nakahama, H; Nakamura, S; Yoshihara, F, 2005) |
| "Candesartan cilexetil is a nonpeptide selective blocker of the angiotensin II receptor sub-type 1." | 2.43 | Candesartan in heart failure. ( Chonlahan, JS; Germany, RE; Ripley, TL, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilous, R | 1 |
| Chaturvedi, N | 1 |
| Sjølie, AK | 1 |
| Fuller, J | 1 |
| Klein, R | 1 |
| Orchard, T | 1 |
| Porta, M | 1 |
| Parving, HH | 1 |
| Mehta, PA | 1 |
| McDonagh, S | 1 |
| Phillips, J | 1 |
| Grocott-Mason, R | 1 |
| Dubrey, SW | 1 |
| Phakdeekitcharoen, B | 1 |
| Leelasa-nguan, P | 1 |
| Fujii, H | 1 |
| Nakahama, H | 1 |
| Yoshihara, F | 1 |
| Nakamura, S | 1 |
| Inenaga, T | 1 |
| Kawano, Y | 1 |
| Desai, AS | 1 |
| Swedberg, K | 2 |
| McMurray, JJ | 2 |
| Granger, CB | 2 |
| Yusuf, S | 2 |
| Young, JB | 1 |
| Dunlap, ME | 1 |
| Solomon, SD | 2 |
| Hainer, JW | 1 |
| Olofsson, B | 2 |
| Michelson, EL | 2 |
| Pfeffer, MA | 2 |
| Ripley, TL | 1 |
| Chonlahan, JS | 1 |
| Germany, RE | 1 |
| Weir, RA | 1 |
| Puu, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.[NCT00252733] | Phase 3 | 5,238 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.[NCT00252694] | Phase 3 | 4,717 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.[NCT00252720] | Phase 3 | 1,850 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 178 |
| Placebo | 217 |
An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.510 |
| Placebo | 0.543 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 161 |
| Placebo | 182 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 180 |
| Placebo | 136 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 192 |
| Placebo | 193 |
An estimate of the slope from fitting a linear regression of log(UAER) over time (post-randomisation, yearly assessments) for each patient. (NCT00252694)
Timeframe: From Baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/1000 year (Least Squares Mean) |
|---|---|
| Candesartan | 656 |
| Placebo | 718 |
Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 127 |
| Placebo | 124 |
Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252720)
Timeframe: From baseline to the end of the study, i.e., 5 years
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 140 |
| Placebo | 139 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 110 |
| Placebo | 107 |
An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.569 |
| Placebo | 0.642 |
1 review available for candesartan and Hyperkalemia
| Article | Year |
|---|---|
Candesartan in heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Death, Sudden; Heart Fa | 2006 |
4 trials available for candesartan and Hyperkalemia
| Article | Year |
|---|---|
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Angiotensin receptor blocker therapy for heart failure patients: is combination treatment a feasible prospect?
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2009 |
Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidaz | 2004 |
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart fa
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Bipheny | 2008 |
2 other studies available for candesartan and Hyperkalemia
| Article | Year |
|---|---|
Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diuretics; Drug Therapy | 2005 |
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2007 |